Moreover, the NFKB pathway has also been shown to be upregulated in CALR mutated MPN HSPCs (24), suggesting that BET inhibition might also be effective in CALR-mutant MPN patients. This evidence concerns the gene NFKB1 and myeloproliferative neoplasm.